PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer
- PDF / 440,542 Bytes
- 8 Pages / 595.28 x 793.7 pts Page_size
- 61 Downloads / 180 Views
RESEARCH
Open Access
PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer Dan Su1,2, Haiyan Xu2, Jianguo Feng2, Yun Gao2, Linhui Gu2, Lisha Ying2, Dionyssios Katsaros3, Herbert Yu4, Shenhua Xu2* and Ming Qi1,5*
Abstract Background: Programmed cell death 6 (PDCD6) beside its known proapoptotic functions may be a player in survival pathways in cancer. The purpose of this study is to further explore the roles of PDCD6 in epithelial ovarian cancer. Methods: Lentiviral vector with shRNA for PDCD6 was used to investigate the effects of PDCD6 knockdown on cell growth, cell cycle, apoptosis and motility in ovarian cancer cells. Two hundred twelve epithelial ovarian cancer tissues were analyzed for mRNA expression of PDCD6 using RT-PCR. Associations of its expression with clinical pathological factors, progression free and overall survival were evaluated. Results: PDCD6 is highly expressed in metastatic ovarian cancer cells and positively regulates cell migration and invasion. Significantly, the level of PDCD6 expression in epithelial ovarian cancer correlates with clinical progression. Patients with medium or high levels of PDCD6 mRNA were at higher risk for disease progression, compared to those with low levels (HR, 1.29; P = 0.024 for medium levels; and HR, 1.57; P = 0.045 for high levels) after adjusting for age, disease stage, tumor grade, histologic type and residual tumor size. Kaplan-Meier survival analysis demonstrated similar results. However, no association was found between PDCD6 expression and overall survival. Conclusions: PDCD6 seems to play an important role in ovarian cancer progression and it may be an independent predictor of progression free survival in epithelial ovarian cancer. Further studies are needed to more completely elucidate the molecular mechanisms of PDCD6 involve in ovarian cancer progression.
Background Ovarian cancer is a common gynecologic malignancy and a major cause of cancer death among women in the United States [1]. The 5-year survival rate for patients with ovarian cancer is only 35% [2,3]. The high mortality of ovarian cancer is related to our inability to detect the disease early and to treat it effectively. Most of ovarian cancer patients ultimately die from tumor recurrence and metastasis, despite the fact that they initially respond to the treatment of cytoreductive surgery followed by paclitaxel and platinum-based chemotherapy. * Correspondence: [email protected]; [email protected] 1 Center for Genetic and Genomic Medicine, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China 2 Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China Full list of author information is available at the end of the article
So, understanding the molecular mechanisms involving the initiation, progression, and metastasis of ovarian cancer is important for the prevention, detection, and treatment of ovarian cancer. In our previous study, two epithelia ovarian cancer cell lines with low and high metastatic potentials
Data Loading...
